DrugPatentWatch Database Preview
Patent: 10,085,983
» See Plans and Pricing
Summary for Patent: 10,085,983
| Title: | Azabicyclo derivatives, process for preparation thereof and medical use thereof |
| Abstract: | Azabicyclo derivatives, a preparation process, and medical use thereof are provided. In particular, azabicyclo derivatives of formula (I), pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs thereof are described. The azabicyclo derivatives of formula (I) are useful as Epidermal Growth Factor Receptor (EGFR) inhibitors. The definitions of the variable R groups in the azabicyclo derivatives of formula (I) are described in the specification. ##STR00001## |
| Inventor(s): | Jin; Yunzhou (Pudong New Area Shanghai, CN), Bu; Ping (Pudong New Area Shanghai, CN), He; Qi (Pudong New Area Shanghai, CN), Lan; Jiong (Pudong New Area Shanghai, CN), Zhou; Fusheng (Pudong New Area Shanghai, CN), Zhang; Liang (Pudong New Area Shanghai, CN), He; Xiangyu (Pudong New Area Shanghai, CN) |
| Assignee: | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (Shanghai, CN) Yangtze River Pharmaceutical Group Co., Ltd. (Jiangsu, CN) |
| Application Number: | 15/515,767 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,085,983
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | HERCEPTIN HYLECTA | trastuzumab; hyaluronidase-oysk | INJECTABLE;SUBCUTANEOUS | 761106 | 001 | 2019-02-28 | Start Trial | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (Shanghai, CN) Yangtze River Pharmaceutical Group Co., Ltd. (Jiangsu, CN) | 2034-09-30 | RX | search | |
| Genentech | PERJETA | pertuzumab | VIAL; SINGLE-USE | 125409 | 001 | 2012-06-08 | Start Trial | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (Shanghai, CN) Yangtze River Pharmaceutical Group Co., Ltd. (Jiangsu, CN) | 2034-09-30 | RX | search | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 003 | 2006-09-27 | Start Trial | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (Shanghai, CN) Yangtze River Pharmaceutical Group Co., Ltd. (Jiangsu, CN) | 2034-09-30 | RX | search | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 002 | 2006-09-27 | Start Trial | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (Shanghai, CN) Yangtze River Pharmaceutical Group Co., Ltd. (Jiangsu, CN) | 2034-09-30 | RX | search | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 001 | 2006-09-27 | Start Trial | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (Shanghai, CN) Yangtze River Pharmaceutical Group Co., Ltd. (Jiangsu, CN) | 2034-09-30 | RX | search | |
| Imclone | ERBITUX | cetuximab | VIAL; INTRAVENOUS | 125084 | 001 | 2004-06-18 | Start Trial | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (Shanghai, CN) Yangtze River Pharmaceutical Group Co., Ltd. (Jiangsu, CN) | 2034-09-30 | RX | Orphan | search |
| Genentech | HERCEPTIN | trastuzumab | VIAL; INTRAVENOUS | 103792 | 001 | 1998-09-25 | Start Trial | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (Shanghai, CN) Yangtze River Pharmaceutical Group Co., Ltd. (Jiangsu, CN) | 2034-09-30 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 10,085,983
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2016050165 | Start Trial |
| United States of America | 2017296537 | Start Trial |
| Japan | 2017530136 | Start Trial |
| Japan | 6342069 | Start Trial |
| European Patent Office | 3202767 | Start Trial |
| China | 105524068 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
